Cingulate Inc.(CING)

Biotechnology · Kansas City, KS

$4.75-0.01 (-0.21%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T13:25:57.814Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:25:57.814Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 63,977,921
Total debt · period ending 2026-06-30: 6,290,880
Cash · period ending 2026-06-30: 28,402,819
TTM operating income · period ending 2026-06-30: -24,920,296

FMP input reference: f1b6469add1457cabf137e6e5cfb012e486d3d2c84b47330ed8a9effb8bf14c7

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CING EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

CING Competitors' EV/EBIT Ratio

CING

Cingulate Inc.

Current

Market Cap

$63.98M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INCR

InterCure Ltd.

vs CING

Market Cap

$64.56M

EV/EBIT Ratio

N/A

TTM Avg

9.73x

3Y Avg

23.03x

5Y Avg

21.55x

GOSS

Gossamer Bio, Inc.

vs CING

Market Cap

$65.08M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KLRS

Kalaris Therapeutics Inc

vs CING

Market Cap

$61.77M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALPS

Alps Group Inc

vs CING

Market Cap

$66.56M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDSB

PDS Biotechnology Corporation

vs CING

Market Cap

$67.11M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INKT

MiNK Therapeutics, Inc.

vs CING

Market Cap

$60.78M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACET

Adicet Bio, Inc.

vs CING

Market Cap

$60.48M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GUTS

Fractyl Health, Inc.

vs CING

Market Cap

$60.29M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CSBR

Champions Oncology, Inc.

vs CING

Market Cap

$69.05M

EV/EBIT Ratio

N/A

TTM Avg

25.28x

3Y Avg

28.49x

5Y Avg

157.43x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Cingulate Inc. (CING)	$63.98M	N/A	N/A	N/A	N/A
InterCure Ltd. (INCR)vs ›	$64.56M	N/A	9.73x	23.03x	21.55x
Gossamer Bio, Inc. (GOSS)vs ›	$65.08M	N/A	N/A	N/A	N/A
Kalaris Therapeutics Inc (KLRS)vs ›	$61.77M	N/A	N/A	N/A	N/A
Alps Group Inc (ALPS)vs ›	$66.56M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$67.11M	N/A	N/A	N/A	N/A
MiNK Therapeutics, Inc. (INKT)vs ›	$60.78M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$60.48M	N/A	N/A	N/A	N/A
Fractyl Health, Inc. (GUTS)vs ›	$60.29M	N/A	N/A	N/A	N/A
Champions Oncology, Inc. (CSBR)vs ›	$69.05M	N/A	25.28x	28.49x	157.43x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

CING EV/EBIT Ratio Metrics

CING Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics